Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Staphylococcus spp.

Infections due to resistant and multidrug resistant (MDR) organisms in haematology patients and haematopoietic stem cell transplant recipients are an increasingly complex problem of global concern. We outline the burden of illness and epidemiology of resistant organisms such as gram-negative pathogens, vancomycin-resistant Enterococcus faecium (VRE), and Clostridium difficile in haematology cohorts. Intervention strategies aimed at reducing the impact of these organisms are reviewed: infection prevention programmes, screening and fluoroquinolone prophylaxis. The role of newer therapies (e.g. linezolid, daptomycin and tigecycline) for treatment of resistant and MDR organisms in haematology populations is evaluated, in addition to the mobilization of older agents (e.g. colistin, pristinamycin and fosfomycin) and the potential benefit of combination regimens.

show abstract

“…Majority of data for suppressive therapy for resistant CoNS, MRSA or VRE bone and joint infections [150,151].…”

Section: Tablementioning

confidence: 99%

The prevention and management of infections due to multidrug resistant organisms in haematology patients

Trubiano

Worth

Thursky

et al. 2015

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…This antibiotic is effective against Staphylococci and Streptococci resisting erythromycin and Staphylococcus aureus resisting methicillin [2][3][4]. The main components of the PI and PII groups were PI A and PII A , respectively.…”

Section: Introductionmentioning

confidence: 99%

Glycine feeding improves pristinamycin production during fermentation including resin for in situ separation

Zhang

Jin

Chen

et al. 2011

Bioprocess Biosyst Eng

View full text Add to dashboard Cite

Seven amino acids were tested as precursors to affect pristinamycin production by a mutant strain derived from Streptomyces pristinaespiralis ATCC25486. Of those, glycine was selected as the best precursor to facilitate both cell growth and pristinamycin production at the feeding time of 36-h incubation and the feeding rate of 0.75 g L -1 flask culture. The optimized time and concentration of glycine feeding were applied to enlarged 3-L bioreactor fermentation with a resin added at the time of 20-h fermentation for in situ separation. As a result, a combination of the glycine feeding and the added resin resulted in the maximal pristinamycin yield of 616 mg L -1 culture 12 h after glycine feeding. The yield from the combined treatment was 1.71-, 2.77-and 4.32-fold of those from the mere glycine and resin treatments and the control, respectively. Other parameters, including intracellular nucleic acid content, animo nitrogen content and pH level, during 72-h fermentation were also given in association with the pristinamycin yields in the different treatments. The results indicate that glycine feeding is an effective approach to enhance pristinamycin production in the culture of S. pristinaespiralis F213 with supplemented resin for in situ separation.

show abstract

“…There is no standardized testing method for pristinamycin susceptibility. Testing for in vitro susceptibility to quinupristin-dalfopristin by Vitek 2 was used as a proxy for pristinamycin susceptibility (7,9). Other antibiotic susceptibilities were determined according to standard NCCLS criteria.…”

mentioning

confidence: 99%

“…To date, only three studies describing the clinical utility of pristinamycin have been published in the English-language literature (3,7,9). Two describe the use of pristinamycin for osteoarticular infections (7,9).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Use of Pristinamycin for Infections by Gram-Positive Bacteria: Clinical Experience at an Australian Hospital

Reid

Daffy

Stanley

et al. 2010

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Thirty-six patients were treated with pristinamycin for 46 different microbiological isolates between April 2007 and July 2009. Pathogens included 9 methicillin-resistant Staphylococcus aureus isolates, 13 methicillin-resistant coagulase negative staphylococci, and 9 vancomycin-resistant enterococci. Sites of infections included 12 osteomyelitis cases, 10 prosthetic joints, 4 other prostheses, and 1 epidural abscess. Five patients ceased treatment due to side effects. Ten patients were cured of their infections, and 21 patients had infections successfully suppressed.

show abstract

Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Staphylococcus spp.

Abstract: Oral pristinamycin is well tolerated and an important additional agent to treat osteoarticular infections with multiresistant MRSA and other staphylococci.

Cited by 44 publications

References 17 publications

The prevention and management of infections due to multidrug resistant organisms in haematology patients

The prevention and management of infections due to multidrug resistant organisms in haematology patients

Glycine feeding improves pristinamycin production during fermentation including resin for in situ separation

Use of Pristinamycin for Infections by Gram-Positive Bacteria: Clinical Experience at an Australian Hospital

Contact Info

Product

Resources

About